201 related articles for article (PubMed ID: 36434608)
21. FKBP5 as a selection biomarker for gemcitabine and Akt inhibitors in treatment of pancreatic cancer.
Hou J; Wang L
PLoS One; 2012; 7(5):e36252. PubMed ID: 22590527
[TBL] [Abstract][Full Text] [Related]
22. Targeting the Janus-activated kinase-2-STAT3 signalling pathway in pancreatic cancer using the HSP90 inhibitor ganetespib.
Nagaraju GP; Mezina A; Shaib WL; Landry J; El-Rayes BF
Eur J Cancer; 2016 Jan; 52():109-19. PubMed ID: 26682870
[TBL] [Abstract][Full Text] [Related]
23. Long non-coding RNA SNHG16 decreased SMAD4 to induce gemcitabine resistance in pancreatic cancer via EZH2-mediated epigenetic modification.
Yu Y; Zou YF; Hong RQ; Chen WJ; Chen L; Chen WQ; Wang HP; Yu Y
Kaohsiung J Med Sci; 2022 Oct; 38(10):981-991. PubMed ID: 36053032
[TBL] [Abstract][Full Text] [Related]
24. Long noncoding RNA ABHD11-AS1 predicts the prognosis of pancreatic cancer patients and serves as a promoter by activating the PI3K-AKT pathway.
Qiao X; Lv SX; Qiao Y; Li QP; Ye B; Wang CC; Miao L
Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8630-8639. PubMed ID: 30575903
[TBL] [Abstract][Full Text] [Related]
25. CDK-4 inhibitor P276 sensitizes pancreatic cancer cells to gemcitabine-induced apoptosis.
Subramaniam D; Periyasamy G; Ponnurangam S; Chakrabarti D; Sugumar A; Padigaru M; Weir SJ; Balakrishnan A; Sharma S; Anant S
Mol Cancer Ther; 2012 Jul; 11(7):1598-608. PubMed ID: 22532602
[TBL] [Abstract][Full Text] [Related]
26. USP39, a direct target of microRNA-133a, promotes progression of pancreatic cancer via the AKT pathway.
Cai J; Liu T; Huang P; Yan W; Guo C; Xiong L; Liu A
Biochem Biophys Res Commun; 2017 Apr; 486(1):184-190. PubMed ID: 28286270
[TBL] [Abstract][Full Text] [Related]
27. The long non-coding RNA HOTTIP promotes progression and gemcitabine resistance by regulating HOXA13 in pancreatic cancer.
Li Z; Zhao X; Zhou Y; Liu Y; Zhou Q; Ye H; Wang Y; Zeng J; Song Y; Gao W; Zheng S; Zhuang B; Chen H; Li W; Li H; Li H; Fu Z; Chen R
J Transl Med; 2015 Mar; 13():84. PubMed ID: 25889214
[TBL] [Abstract][Full Text] [Related]
28. LncRNA PVT1 promotes gemcitabine resistance of pancreatic cancer via activating Wnt/β-catenin and autophagy pathway through modulating the miR-619-5p/Pygo2 and miR-619-5p/ATG14 axes.
Zhou C; Yi C; Yi Y; Qin W; Yan Y; Dong X; Zhang X; Huang Y; Zhang R; Wei J; Ali DW; Michalak M; Chen XZ; Tang J
Mol Cancer; 2020 Jul; 19(1):118. PubMed ID: 32727463
[TBL] [Abstract][Full Text] [Related]
29. TRIM59 predicts poor prognosis and promotes pancreatic cancer progression via the PI3K/AKT/mTOR-glycolysis signaling axis.
Li R; Weng L; Liu B; Zhu L; Zhang X; Tian G; Hu L; Li Q; Jiang S; Shang M
J Cell Biochem; 2020 Feb; 121(2):1986-1997. PubMed ID: 31693252
[TBL] [Abstract][Full Text] [Related]
30. Ursolic acid inhibits growth and induces apoptosis in gemcitabine-resistant human pancreatic cancer via the JNK and PI3K/Akt/NF-κB pathways.
Li J; Liang X; Yang X
Oncol Rep; 2012 Aug; 28(2):501-10. PubMed ID: 22641480
[TBL] [Abstract][Full Text] [Related]
31. Regulation of cell apoptosis and proliferation in pancreatic cancer through PI3K/Akt pathway via Polo-like kinase 1.
Mao Y; Xi L; Li Q; Cai Z; Lai Y; Zhang X; Yu C
Oncol Rep; 2016 Jul; 36(1):49-56. PubMed ID: 27220401
[TBL] [Abstract][Full Text] [Related]
32. Integrin β1 promotes gemcitabine resistance in pancreatic cancer through Cdc42 activation of PI3K p110β signaling.
Yang D; Tang Y; Fu H; Xu J; Hu Z; Zhang Y; Cai Q
Biochem Biophys Res Commun; 2018 Oct; 505(1):215-221. PubMed ID: 30243721
[TBL] [Abstract][Full Text] [Related]
33. Alteration of the intrinsic apoptosis pathway is involved in Notch-induced chemoresistance to gemcitabine in pancreatic cancer.
Du X; Zhao YP; Zhang TP; Zhou L; Chen G; Wang TX; You L; Shu H
Arch Med Res; 2014 Jan; 45(1):15-20. PubMed ID: 24316112
[TBL] [Abstract][Full Text] [Related]
34. Involvement of elevated ASF1B in the poor prognosis and tumorigenesis in pancreatic cancer.
Wang K; Hao Z; Fu X; Li W; Jiao A; Hua X
Mol Cell Biochem; 2022 Jul; 477(7):1947-1957. PubMed ID: 35362843
[TBL] [Abstract][Full Text] [Related]
35. RNF7 Facilitated the Tumorigenesis of Pancreatic Cancer by Activating PI3K/Akt Signaling Pathway.
Hua H; Xie H; Zheng J; Lei L; Deng Z; Yu C
Oxid Med Cell Longev; 2023; 2023():1728463. PubMed ID: 36644576
[TBL] [Abstract][Full Text] [Related]
36. HIF-1α-regulated stanniocalcin-1 mediates gemcitabine resistance in pancreatic ductal adenocarcinoma via PI3K/AKT signaling pathway.
Zhao F; Yang G; Qiu J; Liu Y; Tao J; Chen G; Su D; You L; Zheng L; Zhang T; Zhao Y
Mol Carcinog; 2022 Sep; 61(9):839-850. PubMed ID: 35785493
[TBL] [Abstract][Full Text] [Related]
37. Integrinβ1 modulates tumour resistance to gemcitabine and serves as an independent prognostic factor in pancreatic adenocarcinomas.
Yang D; Shi J; Fu H; Wei Z; Xu J; Hu Z; Zhang Y; Yan R; Cai Q
Tumour Biol; 2016 Sep; 37(9):12315-12327. PubMed ID: 27289231
[TBL] [Abstract][Full Text] [Related]
38. TMEM158 promotes pancreatic cancer aggressiveness by activation of TGFβ1 and PI3K/AKT signaling pathway.
Fu Y; Yao N; Ding D; Zhang X; Liu H; Ma L; Shi W; Zhu C; Tang L
J Cell Physiol; 2020 Mar; 235(3):2761-2775. PubMed ID: 31531884
[TBL] [Abstract][Full Text] [Related]
39. Down-regulated microRNA-223 or elevated ZIC1 inhibits the development of pancreatic cancer via inhibiting PI3K/Akt/mTOR signaling pathway activation.
Zhu J; Lv J; Chen J; Zhang X; Ji Y
Cell Cycle; 2020 Nov; 19(21):2851-2865. PubMed ID: 33064959
[No Abstract] [Full Text] [Related]
40. Low‑intensity low‑frequency ultrasound enhances the chemosensitivity of gemcitabine‑resistant ASPC‑1 cells via PI3K/AKT/NF‑κB pathway‑mediated ABC transporters.
Qiu F; Chen J; Cao J; Diao F; Huang P
Oncol Rep; 2020 Sep; 44(3):1158-1168. PubMed ID: 32705228
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]